Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 20/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18606417 | 0.91 | LRRK2 (0.76) | LRRK2 | |
| SCHEMBL18634668 | 0.89 | LRRK2 (0.73) | LRRK2 | |
| SCHEMBL23935006 | 0.89 | LRRK2 (0.73) | LRRK2 | |
| SCHEMBL18634536 | 0.88 | LRRK2 (0.73) | LRRK2 | |
| SCHEMBL18634539 | 0.86 | LRRK2 (0.64) | LRRK2 | |
| SCHEMBL23922643 | 0.86 | LRRK2 (0.64) | LRRK2 | |
| SCHEMBL18634361 | 0.85 | LRRK2 (0.82) | LRRK2 | |
| SCHEMBL18634529 | 0.85 | LRRK2 (0.72) | LRRK2 | |
| SCHEMBL24027303 | 0.85 | LRRK2 (1.00) | LRRK2 | |
| SCHEMBL30154565 | 0.85 | LRRK2 (1.00) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350178-B1 | NOVEL IMIDAZO [4,5-C]QUINOLINE AND IMIDAZO [4,5-C][1,5]NAPHTHYRIDINE DERIVATIVES AS LRRK2 INHIBITORS | PFIZER (US) | 2021-10-20 | — | — | EP | disclosed |
| US-10039753-B2 | Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors | PFIZER INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20170073343-A1 | Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors | PFIZER INC. (US) | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073343-A1 | Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors | LRRK2, PARK7, SNCA | LRRK2 1/4885 |
| US-10039753-B2 | Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors | LRRK2, PARK7, SNCA | LRRK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.